Metformin lowers blood sugar primarily by reducing the amount of glucose your liver produces, while also helping your muscles and fat cells take up glucose more effectively. It has been the most widely prescribed oral medication for type 2 diabetes for decades, and its mechanism turns out to be more layered than researchers initially thought. The drug does not force your pancreas to pump out more insulin, which is part of why it rarely causes dangerously low blood sugar on its own. Instead, it tackles insulin resistance at several biological levels simultaneously.
The Liver Is the Main Target
Your liver constantly makes glucose, even between meals, through a process called gluconeogenesis. In people with insulin resistance, the liver overproduces glucose because insulin’s usual “slow down” signal is not getting through properly. Metformin’s most important job is dialing that overproduction back down.
Research in rats given clinically relevant doses of metformin showed that it inhibits gluconeogenesis from specific fuel sources by shifting the chemical balance inside liver cells, creating what scientists call an increased cytosolic redox state. When researchers reversed that redox shift using a chemical called methylene blue, metformin’s glucose-lowering effect disappeared, confirming the mechanism was not incidental.1Nature Medicine. Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo This pathway operated independently of some of the other cellular targets researchers had previously assumed were essential, including changes in liver energy stores or fat-burning enzyme activity.
There is another piece to the liver story that has received attention for over two decades. Metformin activates an energy-sensing enzyme called AMPK in liver cells. When AMPK switches on, it reduces the activity of enzymes involved in fat production and dials down the expression of genes that drive fat synthesis.2PubMed Central. Role of AMP-activated protein kinase in mechanism of metformin action This matters because excess fat accumulation in the liver is both a cause and a consequence of insulin resistance. By reducing liver fat, metformin helps restore the liver’s sensitivity to insulin over time.
Inside the Mitochondria
To understand what triggers these downstream effects, you have to look at the cell’s power plants: mitochondria. Metformin inhibits a specific part of the mitochondrial energy-production chain known as complex I. This has been one of the most consistently replicated findings in metformin research.3PubMed Central. Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences By partially blocking complex I, metformin reduces the cell’s energy supply just enough to trigger compensatory responses, including AMPK activation and the redox changes that suppress glucose production.
A 2024 study using genetically modified mice made this connection more concrete. Researchers engineered mice that expressed a yeast protein capable of bypassing complex I entirely. When these mice were given metformin, the drug’s usual blood-glucose-lowering effect was abolished, directly demonstrating that complex I inhibition is required for acute glucose lowering in living animals.4PubMed Central. Metformin targets mitochondrial complex I to lower blood glucose levels This was a meaningful step because earlier work had relied on cell cultures and indirect evidence, and some researchers had argued that complex I inhibition was just a side effect rather than the core mechanism.
That said, the picture is not perfectly tidy. The redox-dependent study mentioned earlier found that metformin’s effects on gluconeogenesis can occur at therapeutic doses without measurably altering liver energy charge, which would be the expected downstream marker of complex I inhibition.1Nature Medicine. Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo So while complex I is clearly important for the acute glucose drop, other pathways may carry weight during chronic treatment. The scientific community is still sorting out exactly how these mechanisms interact at different doses and time scales.
How Metformin Helps Muscles and Fat Cells
The liver is where most of the action happens, but metformin also improves glucose uptake in peripheral tissues. Muscle is the body’s largest consumer of glucose, and in insulin resistance, muscle cells struggle to move glucose transporters (called GLUT4) to their surfaces where they can pull glucose in from the bloodstream.
In skeletal muscle cells, metformin activates AMPK, which then sets off a signaling cascade that promotes GLUT4 movement to the cell surface. Studies in muscle cell lines showed that metformin boosted levels of a protein called Rab4 through AMPK signaling, and when Rab4 was knocked out, insulin-stimulated GLUT4 movement was suppressed.5PubMed. Metformin induces Rab4 through AMPK and modulates GLUT4 translocation in skeletal muscle cells A similar mechanism operates in fat cells, where metformin drives GLUT4 to the cell surface through a different AMPK-dependent signaling complex. When researchers knocked down key components of this pathway in fat cells, metformin’s ability to move GLUT4 was blocked.6PubMed Central. Metformin regulates glucose transporter 4 (GLUT4) translocation through AMP-activated protein kinase (AMPK)-mediated Cbl/CAP signaling in 3T3-L1 preadipocyte cells
The practical result is that metformin helps your muscles and fat tissue absorb glucose more efficiently, reducing the amount left circulating in your blood. This effect is complementary to the liver mechanism: your liver makes less glucose, and your peripheral tissues soak up more of what remains.
Effects on Fat Tissue and Inflammation
Insulin resistance is tightly linked to chronic, low-grade inflammation in fat tissue. Enlarged fat cells pump out inflammatory signals that worsen insulin resistance in a vicious cycle. Metformin appears to break into this cycle. In rats fed a high-fat diet, metformin treatment improved insulin sensitivity and was associated with reduced levels of inflammatory lipids in both the fat stored under the skin and the deeper visceral fat around the organs. The drug also raised adiponectin, a hormone released by fat cells that promotes insulin sensitivity, and brought the inflammatory marker TNF-alpha back down to normal levels.7Nutrition. Metformin treatment affects adipocytokine secretion and lipid composition in adipose tissues of diet-induced insulin-resistant rats
Metformin also appears to help with fatty liver, which is increasingly common alongside insulin resistance. In a mouse model of high-fat-diet-induced liver disease, metformin treatment reversed fat accumulation in the liver and restored insulin sensitivity by promoting a cellular cleanup process called autophagy, where cells break down and recycle damaged components.8PubMed Central. Metformin Alleviates Hepatic Steatosis and Insulin Resistance in a Mouse Model of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Promoting Transcription Factor EB-Dependent Autophagy This cleanup is important because the accumulation of toxic lipids in the liver is one of the key drivers of worsening insulin resistance over time.
The Gut Connection
Researchers have increasingly recognized that metformin does not just pass through your gut on its way to the liver. It actually works inside the gut in meaningful ways. In diabetic mice, metformin treatment increased the number of cells in the colon that produce GLP-1, a hormone that stimulates insulin release and suppresses appetite. A high-fat diet had suppressed the gene responsible for making GLP-1, and metformin restored its expression at higher doses.9Molecular Metabolism. Evaluation of the effects of metformin on gut functions and microbiota and their contribution to improving glucose tolerance in diabetic mice
This gut-level action may explain something that has puzzled clinicians: metformin’s blood-glucose-lowering effect seems disproportionately large compared to what you would predict from the drug’s concentration in the blood alone. A substantial share of the drug accumulates in the intestinal wall, where it may be doing as much work as it does in the liver. It also helps explain why gastrointestinal side effects are so common with metformin: the gut is not just a highway for the drug but one of its primary workplaces.
Why Not Everyone Responds the Same Way
One of the most frustrating aspects of metformin therapy is that it works much better for some people than for others. A significant piece of this variability comes down to a single protein called OCT1, or organic cation transporter 1. OCT1 acts as a doorway that moves metformin into liver cells. Without enough OCT1 activity, metformin cannot get inside the liver in sufficient quantities to do its job.
In mice engineered to lack OCT1, metformin reached the same concentrations in the blood as in normal mice, but accumulated in the liver at roughly one-quarter the normal level. Metformin suppressed liver glucose production by about 30% in normal mice but failed to produce a meaningful effect in the OCT1-deficient animals.10JCI Insight. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action The same study tested human volunteers and found that people carrying certain OCT1 gene variants had significantly higher blood glucose levels after metformin treatment compared to those with the standard version of the gene.
A separate study in diabetes patients found that for each copy of a specific OCT1 variant (rs622342), the reduction in HbA1c from metformin was about 0.28% less.11PubMed. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus That may not sound like much, but HbA1c differences of that size can determine whether someone hits their treatment target. OCT1 variants have also been linked to gastrointestinal side effects, suggesting that when the drug cannot enter liver cells efficiently, more of it stays in the gut, causing discomfort.12PubMed Central. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes
Pharmacogenomic testing for OCT1 variants is not yet standard clinical practice, but it is one of the more promising candidates for personalizing metformin therapy in the future.
Metformin and PCOS
Polycystic ovary syndrome is one of the most common reasons metformin is prescribed outside of type 2 diabetes. PCOS is closely tied to insulin resistance: excess insulin drives the ovaries to produce too much testosterone, which disrupts ovulation. By improving insulin sensitivity, metformin can lower androgen levels, restore more regular menstrual cycles, and help trigger ovulation.13PubMed Central. Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility A Cochrane review confirmed that metformin improves ovulation rates in women with PCOS.14PubMed Central. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome
Recent meta-analysis data suggest that adding a GLP-1 receptor agonist to metformin may produce better improvements in insulin sensitivity and body weight than metformin alone in women with PCOS.15PubMed. Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis But metformin remains a practical first-line option because of its long safety track record, low cost, and the fact that GLP-1 agonists are injectable and substantially more expensive.16International Journal of Innovative Technologies in Social Science. THE COMPREHENSIVE COMPARISON OF THE EFFICACY OF FIRST-LINE DRUGS IN THE TREATMENT OF TYPE II DIABETES: METFORMIN, GLP-1 AGONISTS, AND SGLT2 INHIBITORS
Side Effects and the B12 Question
Gastrointestinal problems are by far the most common complaint with metformin. Nausea, diarrhea, bloating, and stomach cramps affect a meaningful proportion of users, especially in the first weeks. Starting at a low dose and increasing gradually, and taking the medication with food, helps most people adjust. Extended-release formulations also tend to cause fewer gut symptoms than the standard immediate-release tablets.
A less well-known side effect is vitamin B12 depletion. Metformin interferes with B12 absorption in the small intestine by disrupting a calcium-dependent step required for B12 uptake.17PubMed Central. Vitamin B(12) deficiency in diabetic patients treated with metformin: A narrative review Over months or years, this can lead to clinically low B12 levels, which may cause fatigue, numbness, or tingling in the hands and feet. The symptoms can mimic diabetic neuropathy, which means they sometimes go unrecognized. Periodic B12 monitoring is a reasonable precaution for anyone on long-term metformin.
Kidney Function and Lactic Acidosis Risk
Lactic acidosis is the safety concern that gets the most attention with metformin, but it deserves some context. Metformin is cleared almost entirely by the kidneys, with a short half-life of under three hours in people with normal kidney function.18PubMed Central. Metformin, chronic nephropathy and lactic acidosis: a multi-faceted issue for the nephrologist When the kidneys are working normally, the drug exits the body fast enough that dangerous buildup is very unlikely. The real risk emerges when kidney function drops significantly or when an acute illness like severe dehydration, sepsis, or persistent vomiting slows kidney clearance and causes the drug to accumulate.
A large community-based study found that metformin use was not associated with increased acidosis risk overall, or in people with moderately reduced kidney function. The risk only became clearly elevated in those with severely reduced kidney function, roughly doubling in that group.19PubMed Central. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study Current guidelines in most countries allow metformin use down to moderate kidney impairment with dose adjustment, but recommend stopping the drug when kidney function falls below a certain threshold. Your prescriber should be monitoring kidney function periodically if you are on metformin long-term.
Metformin in Adolescents
Rising rates of childhood obesity have made insulin resistance increasingly common in younger age groups. Metformin is approved for type 2 diabetes in adolescents and is sometimes used off-label for obesity-related insulin resistance and PCOS in teenagers.20PubMed Central. The clinical application of metformin in children and adolescents: A short update
An 18-month randomized trial in obese, insulin-resistant adolescents found that metformin modestly limited BMI gain and reduced fat mass compared to placebo. However, it did not significantly improve the standard measure of insulin resistance (HOMA-IR) in that trial. The drug was well tolerated with no serious adverse events reported.21Nutrition & Diabetes. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial This is a reminder that metformin is not a substitute for lifestyle changes in young people. It can be a useful tool, but the evidence for dramatic metabolic improvement in adolescents is more limited than in adults with established type 2 diabetes.
Metformin and Pregnancy
Metformin crosses the placenta, which has understandably raised questions about its safety during pregnancy. It has been used for over 40 years in pregnant women, primarily for gestational diabetes and in women with PCOS who conceive while on the drug. Untreated gestational diabetes carries risks including excessive fetal growth, pregnancy-induced hypertension, and stillbirth. Metformin can help control these risks, sometimes alone and sometimes combined with insulin if blood sugar targets are not met with metformin alone.22PubMed Central. A Review on the Use of Metformin in Pregnancy and Its Associated Fetal Outcomes There is also evidence that women with gestational diabetes face elevated risk of developing type 2 diabetes in the years after delivery, and managing glucose during pregnancy may influence that trajectory.
The long-term effects on children exposed to metformin in utero are still being studied. Some follow-up studies have raised questions about whether exposed children may have slightly different body composition patterns in early childhood, though the clinical significance is not yet settled. Most obstetric guidelines consider metformin an acceptable option when lifestyle modification alone is insufficient.
The Aging Research Frontier
Metformin has attracted serious interest from aging researchers, and this goes well beyond hype. The biological pathways it affects, including AMPK activation, reduced insulin and IGF-1 signaling, suppression of the growth-promoting mTOR pathway, decreased production of reactive oxygen species, and reduction of DNA damage, overlap substantially with the pathways implicated in age-related disease.23PubMed Central. Metformin as a Tool to Target Aging Metformin also promotes autophagy and reduces markers of cellular senescence, both of which are considered central to the biology of aging.24PubMed Central. The Anti-Aging Mechanism of Metformin: From Molecular Insights to Clinical Applications
Animal studies have been encouraging. In one example, mice engineered to age prematurely lost bone density in their jaws alongside disrupted AMPK-mTOR signaling. Metformin treatment normalized that signaling, reduced oxidative stress and markers of cellular aging, and improved the bone architecture.25PubMed Central. Metformin prevents mandibular bone loss in a mouse model of accelerated aging by correcting dysregulated AMPK-mTOR signaling and osteoclast differentiation The TAME (Targeting Aging with Metformin) trial is a large, ongoing human clinical trial designed to test whether metformin can delay the onset of age-related diseases in older adults who do not have diabetes. Results from that trial will be an important test of whether the animal data translate to humans in a clinically meaningful way.
Even if metformin turns out to have modest anti-aging benefits in humans, its safety profile, decades of clinical experience, and low cost make it a uniquely positioned candidate for this kind of research. Most of the other drugs that affect similar pathways, like rapamycin, carry significantly more serious side effect profiles.
A Drug with Botanical Roots
Metformin’s origin story is unusual for a blockbuster pharmaceutical. It traces back to a European medicinal herb called goat’s rue (Galega officinalis), which was found to be rich in guanidine. In 1918, researchers demonstrated that guanidine could lower blood glucose.26PubMed. Metformin: historical overview Guanidine itself was too toxic for clinical use, but chemists eventually refined it into the biguanide family of compounds, of which metformin proved to be the safest and most effective. Two related biguanides, phenformin and buformin, were pulled from most markets in the 1970s due to high rates of lactic acidosis. Metformin survived because its risk of this complication is dramatically lower, a distinction that took decades to fully appreciate. It was not approved in the United States until 1995, long after it had become a mainstay in Europe. The delay was largely due to lingering concerns from its cousins’ track record, not from problems with metformin itself.